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Introduction
Bleomycin-induced pneumonitis (BIP) is a scarcely manageable
pulmonary toxicity that occurs in approximately 20%of patientswho
are affected with cancers that are treated with bleomycin-containing
regimens. Generally, the clinical picture is extremely complicated and
therapy is based on steroids. The overall response rate to such therapy
is limited. Recent insights in BIP pathogenesis have indicated that a
key feature is deregulated mechanisms of tissue repair that are driven
by profibrotic cytokines. Here we describe a patient with life-
threatening BIP who was completely cured with imatinib mesylate
(IM) after steroids and all other therapies had failed.
Case Report
A 65-year-old man with stage IV Hodgkin’s lymphoma (HL;
lymphocyte-depleted variant), already in metabolic complete re-
sponse after a third cycle of doxorubicin, 50 mg/m2; bleomycin, 10
U/m2; vinblastine, 6 mg/m2; and dacarbazine, 375 mg/m2, presented
withprogressive shortnessofbreath, fever, anddrycough3weeksafter
completion of the sixth cycle of therapy. His medical history was
unremarkable. On examination, the patient demonstrated a Karnof-
sky performance status of 50%, body temperature of 38°C, blood
pressure of 120/70 mmHg, pulse rate of 104 beats/min, and respira-
tory rate of 28 breaths/min. Oxygen saturation was 83% at room air
and 93%with a 60%mistmask; arterial blood gases showed pH, 7.47;
PaO2, 64 mm Hg; PCO2, 27 mm Hg; bicarbonate, 22 mmol/L; and
arterial lactate, 2.6 mmol/L. On auscultation, there were crackles and
crepitations across the lower and middle lung fields. The WBC was
14,200/L (reference range, 4,500 to 10,000/L)with anormal differ-
ential count, hematocrit of 24%, and platelet count of 632,000/L
(reference range, 150,000 to400,000/L). Serumlacticdehydrogenase
was 999 UI/L (reference range  620 UI/L) and the C-reactive
protein level was 0.23 g/L (reference range 0.005 g/L). The remain-
ing laboratory results were unremarkable. On admission, a chest ra-
diograph showedbilateral diffuse parenchymal airspacedensitieswith
reticular opacities.Ahigh-resolution computed tomography (HRCT)
scanof thechest (Fig1) showedbilateraldiffuseground-glassopacities
associated with fine interlobular and intralobular reticulations with
honeycomb features. Remarkably, both aCT scan and aCT–positron
emission tomography scan confirmed a radiologic and metabolic
complete response of HL.
On the basis of this clinical picture, broad-spectrum antibiotic
therapy was begun with teicoplanin (initial dose of 400 mg intrave-
nously [IV] every 12 hours and then 800 mg IV once daily) and
meropenem (1 g every 8 hours) along with fluconazole (200 mg IV
every12hours) andacyclovir (500mgIVevery12hours).After7days,
HRCTwasrepeatedandshowedaslight improvementof the lesions in
the upper lobes but no change in the diffuse ground-glass opacities in
the lower lobes. Therefore, a bronchoscopywas performed formicro-
biologic cultures, bronchoalveolar lavage, and cytology evaluation.
Pseudomonas aeruginosa was isolated, whereas both bronchoalveolar
lavage and cytology were negative for either tumoral cells or other
pathogenic microorganisms (including viruses and intracellular bac-
teria). Because the patient’s respiratory condition was progressively
deteriorating, treatment with trimethoprim/sulfamethoxazole (4
mg/kg every 6 hours) and voriconazole (initial dose of 6 mg/kg every
12 hours and then 4mg/kg every 12 hours) was begun on the recom-
mendation of an infectious diseases consultant.
Given that BIPwas suspected, the patientwas evaluated to deter-
mine whether a lung biopsy should be performed; however, the tho-
racic surgeon determined that a lung biopsy was contraindicated
because of the patient’sworsening clinical condition. Therefore, treat-
ment with methylprednisolone 2 mg/kg was also begun. In addition,
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the patient began receiving continuous positive airway pressure oxy-
gen therapy 72 hours later, but there was no clinical improvement by
day6. In lightof this continuous respiratorydeteriorationandbecause
BIPwas considered to be themost likely diagnosis, after a patient care
conference,webegan therapywith300mgof IM,on thebasisof recent
data regarding the effectiveness of IM in the setting of allogeneic
hematopoietic stem-cell transplantation for the treatment of graft-
versus-host–induced lung fibrosis.
After aweekof IM therapy, the clinical picture began to improve,
allowing a reduction inoxygen therapy and then complete suspension
of oxygen therapy 21 days after the start of treatmentwith IM. IMwas
continued for 6 months and resulted in additional improvement in
respiratory function. HRCT scans performed at 3 and 6months (Figs
2 and 3, respectively) showed a continuous improvement of the inter-
stitial lesions until they completely disappeared. Notably, at 3months
the patient was started on moxifloxacin 400 mg once daily for the
onset of asymptomatic focal pneumonia (Fig 2). At the most recent
follow-up, the patient is alive and is still in complete remission forHL,
with a Karnofsky performance status of 100%.
Discussion
Bleomycin-induced lung fibrosis is a major pulmonary toxicity
that occurs in approximately 20% to 40%of patients who are affected
by Hodgkin’s lymphoma (HL) and are treated with a bleomycin-
containing regimen.1,2 The mortality of this complication is high,
ranging from10%to20%, and significantly impacts quality of life and
5-year overall survival.3 The BIP clinical picture is usually character-
ized by dyspnea after exertion, persistent nonproductive cough, and
mild fever. At physical examination, findings may be not specific and
range fromtachypneaonly todry crackles.Generally, thepossibility of
BIP is suggested by chest imaging studies. The presence of respiratory
symptoms and bilateral interstitial infiltrates on CT scans along with
the exclusion of active lung infections (defined as negative cultures
and lack of response to antimicrobials) are the most important
clues to clinical diagnosis. Whenever feasible, the diagnosis relies
on a lung biopsy that demonstrates a heterogeneous appearance
with alternating areas of normal lung, interstitial inflammation,
foci of proliferating fibroblast, dense collagen fibrosis, and honey-
comb changes.4
BIP pathogenesis is unknown, but there is consensus that dereg-
ulated mechanisms of tissue repair driven by profibrotic cytokines
initiate the lung-damaging effects.5,6 Specifically, tumor growth factor
, platelet-derived growth factor receptor  (PDGFR-), and tumor
necrosis factor  are believed to cause transformation, proliferation,
andaccumulationoffibroblastswith thedepositionof anextracellular
matrix.7 The progressive accumulation of this collagen matrix de-
termines distortion and destruction of the alveolar structures and,
eventually, loss of lung function. In animal models, it has been
demonstrated that PDGF- expression is increased in BIP. Finally,
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enhanced expression of PDGFR-was also shown in the epithelial
cells and alveolar macrophages in lungs of patients with idiopathic
pulmonary fibrosis.
Imatinib mesylate is a potent and specific receptor tyrosine ki-
nase inhibitor of ABL, BCR-ABL, KIT, and both isoforms of PDGFR.
Since its first use in chronic myeloid leukemia, IM was proven to be
active in various PDGFR-driven diseases such as GI stromal tumors,
dermatofibrosarcoma protuberans, and chordoma.8,9 The successful
inhibitionofPDGFR thatwas observed in these tumors suggested that
scleroderma-like chronic graft-versus-host disease, a serious adverse
event of allogeneic stem-cell transplantation, might be treatable with
IM.10 Indeed, it is well known that both PDGFR and tumor growth
factor  pathways are actively involved in the pathogenesis of this
complication. The same receptors are involved in idiopathic pulmo-
naryfibrosis,which is apathologiccondition that closely resembles the
final lung damage observed in BIP.11 These speculations prompted us
to test a low-toxicity profile drug such as IM in apatientwhose rapidly
worsening clinical condition had been refractory to all previously
attempted therapies.
Asdescribed in the caseof this patient, thediagnosis of interstitial
lungdiseasesandBIP inparticular is challengingandoftendependson
clinical, radiologic, and cytologic findings, as well as on the absence of
response to all antibiotics used. The extremely favorable clinical
outcome of our patient is noteworthy, and the observed complete
response warrants additional study of IM in the treatment of a
scarcely manageable chronic adverse effect of HL and testicular
cancer treatments.
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